HR Execs on the Move

Immunovant

www.immunovant.com

 
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.immunovant.com
  • 320 West 37th Street 5th Floor
    New York, NY USA 10018
  • Phone: 212.847.6204

Executives

Name Title Contact Details
Kathryn Bednarz
 Director, Clinical Laboratories Profile
Shari Duralek
 Director Global Clincial Supply Chain Profile
Steven Hagler
 Director, Technical Accounting and SEC Reporting Profile
Elise McCarthy
 Associate Director, Vendor Quality Assurance Profile
Daniel Isaacman
 Vice President Clinical Research Profile

Similar Companies

Exagen Diagnostics Inc.

Exagen Diagnostics Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

SaskWater

SaskWater is a Moose Jaw, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Tyme

TYME, Inc. is a pharmaceutical company focused on creating medicines that specialize in using the body’s immune system to treat diseases. The body has the ability to fight off major diseases and heal itself. Tyme is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. Tyme hopes to provide a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers (breast, lung, prostrate, gastric, esophageal and pancreatic cancers) responsible for 62% of the annual cancer deaths in the United States. The SM-88, Tyme’s proprietary compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. SM-88 is designed to penetrate the living cancer cells and introduce multiple mechanisms to kill the cell. Inducing transfer of electrons in the cancer cells may allow catalyzed external free radicals to react and stress the cell. SM-88 is a combination of low dose agents used for non-cancer treatment.

In Vivo Scientific

In Vivo Scientific is a Valley Park, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unipex Solutions

Unipex Solutions is a Quí©bec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.